Photoacoustic tomography detects early vessel regression and normalization during ovarian tumor response to the antiangiogenic therapy trebananib

Journal of Nuclear Medicine

Volumn 56, Issue 12, 2015, Pages 1942-1947

  Bohndiek, Sarah E ^a   Sasportas, Laura S ^a   Machtaler, Steven ^a   Jokerst, Jesse V ^a   Hori, Sharon ^a   Gambhir, Sanjiv S ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiogenesis; Angiopoietin; Ovarian cancer; Photoacoustics

Indexed keywords

ANGIOPOIETIN 1; ANGIOPOIETIN 2; CD31 ANTIGEN; DEOXYHEMOGLOBIN; HEMOGLOBIN; OXYHEMOGLOBIN; TREBANANIB; ANGIOGENESIS INHIBITOR; HYBRID PROTEIN;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC THERAPY; ARTICLE; BLOOD OXYGENATION; CANCER REGRESSION; CAPILLARY DENSITY; CELL DEATH; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMAGE QUALITY; IN VIVO STUDY; MOUSE; NON INVASIVE PROCEDURE; NONHUMAN; OVARY CANCER; PHOTOACOUSTIC TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TISSUE LEVEL; TREATMENT RESPONSE; ANIMAL; BLOOD; BLOOD FLOW; BLOOD VESSEL; DEVICES; DRUG EFFECTS; IMAGE PROCESSING; LUMINESCENCE; METABOLISM; OVARIAN NEOPLASMS; PATHOLOGY; PHOTOACOUSTICS; PROCEDURES; TUMOR CELL LINE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANGIOPOIETIN-1; ANIMALS; BLOOD VESSELS; CELL LINE, TUMOR; FEMALE; HEMOGLOBINS; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; LUMINESCENCE; MICE; OVARIAN NEOPLASMS; PHOTOACOUSTIC TECHNIQUES; RECOMBINANT FUSION PROTEINS; REGIONAL BLOOD FLOW;

EID: 84958267959     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.160002     Document Type: Article

References (38)

1. Wang LV, Hu S. Photoacoustic tomography: in vivo imaging from organelles to organs. Science. 2012;335:1458-1462.
2. Chen SL, Burnett J, Sun D, et al. Photoacoustic microscopy: a potential new tool for evaluation of angiogenesis inhibitor. Biomed Opt Express. 2013;4:2657-2666.
3. Laufer J, Johnson P, Zhang E, et al. In vivo preclinical photoacoustic imaging of tumor vasculature development and therapy. J Biomed Opt. 2012;17:056016.
4. Rich LJ, Seshadri M. Photoacoustic imaging of vascular hemodynamics: validation with blood oxygenation level-dependent MR imaging. Radiology. 2015;275: 110-118.
5. Herzog E, Taruttis A, Beziere N, et al. Optical imaging of cancer heterogeneity with multispectral optoacoustic tomography. Radiology. 2012;263:461-468.
6. Kruger RA, Lam RB, Reinecke DR, et al. Photoacoustic angiography of the breast. Med Phys. 2010;37:6096-6100.
7. Heijblom M, Piras D, Xia W, et al. Visualizing breast cancer using the Twente photoacoustic mammoscope: what do we learn from twelve new patient measurements? Opt Express. 2012;20:11582-11597.
8. Zackrisson S, van de Ven SM, Gambhir SS. Light in and sound out: emerging translational strategies for photoacoustic imaging. Cancer Res. 2014;74:979-1004.
9. Aguirre A, Ardeshirpour Y, Sanders MM, et al. Potential role of coregistered photoacoustic and ultrasound imaging in ovarian cancer detection and characterization. Transl Oncol. 2011;4:29-37.
10. Aguirre A, Guo P, Gamelin J, et al. Coregistered three-dimensional ultrasound and photoacoustic imaging system for ovarian tissue characterization. J Biomed Opt. 2009;14:054014.
11. Teoh D, Secord AA. Antiangiogenic agents in combination with chemotherapy for the treatment of epithelial ovarian cancer. Int J Gynecol Cancer. 2012;22: 348-359.
12. Ramakrishnan S, Subramanian IV, Yokoyama Y, et al. Angiogenesis in normal and neoplastic ovaries. Angiogenesis. 2005;8:169-182.
13. Taylor SE, Kirwan JM. Ovarian cancer: current management and future directions. Obstetrics, Gynaecol Reprod Med. 2009;19:130-135.
14. Yap TA, Carden CP, Kaye SB. Beyond chemotherapy: targeted therapies in ovarian cancer. Nat Rev Cancer. 2009;9:167-181.
15. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangio-genic therapy. Science. 2005;307:58-62.
16. Augustin HG, Koh GY, Thurston G, et al. Control of vascular morphogenesis and homeostasis through the angiopoietin-Tie system. Nat Rev Mol Cell Biol. 2009;10:165-177.
17. Huang H, Bhat A, Woodnutt G, et al. Targeting the ANGPT-TIE2 pathway in malignancy. Nat Rev Cancer. 2010;10:575-585.
18. Karam AK, Karlan BY. Ovarian cancer: the duplicity of CA125 measurement. Nat Rev Clin Oncol. 2010;7:335-339.
19. Bohndiek SE, Brindle KM. Imaging and 'omic' methods for the molecular diagnosis of cancer. Expert Rev Mol Diagn. 2010;10:417-434.
20. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
21. Ehling J, Lammers T, Kiessling F. Non-Invasive imaging for studying anti-angiogenic therapy effects. Thromb Haemost. 2013;109:375-390.
22. Maisonpierre PC, Suri C, Jones PF, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277:55-60.
23. Coxon A, Bready J, Min H, et al. Context-dependent role of angiopoietin-1 inhibition in the suppression of angiogenesis and tumor growth: implications for AMG 386, an angiopoietin-1/2-neutralizing peptibody. Mol Cancer Ther. 2010;9:2641-2651.
24. Davis S, Aldrich TH, Jones PF, et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell. 1996;87:1161-1169.
25. Azzi S, Hebda JK, Gavard J. Vascular permeability and drug delivery in cancers. Front Oncol. 2013;3:211.
26. Daly C, Eichten A, Castanaro C, et al. Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition. Cancer Res. 2013;73:108-118.
27. Hashizume H, Falcon BL, Kuroda T, et al. Complementary actions of inhibitors of angiopoietin-2 and VEGF on tumor angiogenesis and growth. Cancer Res. 2010;70:2213-2223.
28. Nasarre P, Thomas M, Kruse K, et al. Host-derived angiopoietin-2 affects early stages of tumor development and vessel maturation but is dispensable for later stages of tumor growth. Cancer Res. 2009;69:1324-1333.
29. Oliner J, Min H, Leal J, et al. Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2. Cancer Cell. 2004;6:507-516.
30. Herbst RS, Hong D, Chap L, et al. Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors. J Clin Oncol. 2009;27:3557-3565.
31. Karlan BY, Oza AM, Richardson GE, et al. Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer. J Clin Oncol. 2012;30:362-371.
32. Falcón BL, Hashizume H, Koumoutsakos P, et al. Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Am J Pathol. 2009;175:2159-2170.
33. Shaw TJ, Senterman MK, Dawson K, et al. Characterization of intraperitoneal, orthotopic, and metastatic xenograft models of human ovarian cancer. Mol Ther. 2004;10:1032-1042.
34. Nilsson EE, Westfall SD, McDonald C. Liet al. An in vivo mouse reporter gene (human secreted alkaline phosphatase) model to monitor ovarian tumor growth and response to therapeutics. Cancer Chemother Pharmacol. 2002;49:93-100.
35. 13C spectros-copy detects early changes in tumor vasculature and metabolism after VEGF neutralization. Cancer Res. 2012;72:854-864.
36. Shim WS, Teh M, Bapna A, et al. Angiopoietin 1 promotes tumor angiogenesis and tumor vessel plasticity of human cervical cancer in mice. Exp Cell Res. 2002;279:299-309.
37. Suri C, McClain J, Thurston G, et al. Increased vascularization in mice over-expressing angiopoietin-1. Science. 1998;282:468-471.
38. Drickamer LC. Seasonal variation in litter size, bodyweight and sexual maturation in juvenile female house mice (Mus musculus). Lab Anim. 1977;11: 159-162.